Literature DB >> 10359665

Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo.

E A Biessen1, H Vietsch, E T Rump, K Fluiter, J Kuiper, M K Bijsterbosch, T J van Berkel.   

Abstract

Anti-sense oligodeoxynucleotides (ODNs) hold great promise for correcting the biosynthesis of clinically relevant proteins. The potential of ODNs for modulating liver-specific genes might be increased by preventing untimely elimination and by improving the local bioavailability of ODNs in the target tissue. In the present study we have assessed whether the local ODN concentration can be enhanced by the targeted delivery of ODNs through conjugation to a ligand for the parenchymal liver cell-specific asialoglycoprotein receptor. A capped ODN (miscellaneous 20-mer sequence) was derivatized with a ligand with high affinity for this receptor, N2-[N2-(N2,N6-bis{N-[p-(beta-d-galactopyranosyloxy) anilino] thiocarbamyl}-L-lysyl)-N6-(N-{p-[beta-D -galactopyranosyloxy] anilino} thiocarbamyl)-L-lysyl]-N6-[N- (p-{beta-D-galactopyranosyloxy}anilino)thiocarbamyl]-L-lysine (L3G4) (Kd 6.5+/-0.2 nM, mean+/-S.D.). Both the uptake studies in vitro and the confocal laser scan microscopy studies demonstrated that L3G4-ODN was far more efficiently bound to and taken up by parenchymal liver cells than underivatized ODN. Studies in vivo in rats showed that hepatic uptake could be greatly enhanced from 19+/-1% to 77+/-6% of the injected dose after glycoconjugation. Importantly, specific ODN accumulation of ODN into parenchymal liver cells was improved almost 60-fold after derivatization with L3G4, and could be attributed to the asialoglycoprotein receptor. In conclusion, the scavenger receptor-mediated elimination pathway for miscellaneous ODN sequences can be circumvented by direct conjugation to a synthetic tag for the asialoglycoprotein receptor. In this manner a crucial requisite is met towards the application of ODNs in vivo to modulate the biosynthesis of parenchymal liver cell-specific genes such as those for apolipoprotein (a), cholesterol ester transfer protein and viral proteins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10359665      PMCID: PMC1220312     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  42 in total

1.  Evaluation of physicochemical parameters important to the oral bioavailability of peptide-like compounds: implications for the synthesis of renin inhibitors.

Authors:  H W Hamilton; B A Steinbaugh; B H Stewart; O H Chan; H L Schmid; R Schroeder; M J Ryan; J Keiser; M D Taylor; C J Blankley
Journal:  J Med Chem       Date:  1995-04-28       Impact factor: 7.446

Review 2.  Current concepts in antisense drug design.

Authors:  J F Milligan; M D Matteucci; J C Martin
Journal:  J Med Chem       Date:  1993-07-09       Impact factor: 7.446

Review 3.  Gene inhibition using antisense oligodeoxynucleotides.

Authors:  R W Wagner
Journal:  Nature       Date:  1994-11-24       Impact factor: 49.962

4.  Targeted delivery of DNA using YEE(GalNAcAH)3, a synthetic glycopeptide ligand for the asialoglycoprotein receptor.

Authors:  J R Merwin; G S Noell; W L Thomas; H C Chiou; M E DeRome; T D McKee; G L Spitalny; M A Findeis
Journal:  Bioconjug Chem       Date:  1994 Nov-Dec       Impact factor: 4.774

5.  Biodistribution and metabolism of internally 3H-labeled oligonucleotides. II. 3',5'-blocked oligonucleotides.

Authors:  H Sands; L J Gorey-Feret; S P Ho; Y Bao; A J Cocuzza; D Chidester; F W Hobbs
Journal:  Mol Pharmacol       Date:  1995-03       Impact factor: 4.436

6.  Specific targeting of the antiviral drug 5-iodo 2'-deoxyuridine to the parenchymal liver cell using lactosylated poly-L-lysine.

Authors:  E A Biessen; D M Beuting; H Vietsch; M K Bijsterbosch; T J Van Berkel
Journal:  J Hepatol       Date:  1994-11       Impact factor: 25.083

Review 7.  Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

Authors:  C A Stein; Y C Cheng
Journal:  Science       Date:  1993-08-20       Impact factor: 47.728

8.  Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia.

Authors:  A M Tari; S D Tucker; A Deisseroth; G Lopez-Berestein
Journal:  Blood       Date:  1994-07-15       Impact factor: 22.113

9.  Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes.

Authors:  O Zelphati; E Wagner; L Leserman
Journal:  Antiviral Res       Date:  1994-09       Impact factor: 5.970

10.  Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery.

Authors:  R Morishita; G H Gibbons; Y Kaneda; T Ogihara; V J Dzau
Journal:  Gene       Date:  1994-11-04       Impact factor: 3.688

View more
  15 in total

1.  Receptor-mediated endocytosis of phosphodiester oligonucleotides in the HepG2 cell line: evidence for non-conventional intracellular trafficking.

Authors:  Philippe de Diesbach; Francisca N'Kuli; Catherine Berens; Etienne Sonveaux; Michel Monsigny; Annie-Claude Roche; Pierre J Courtoy
Journal:  Nucleic Acids Res       Date:  2002-04-01       Impact factor: 16.971

Review 2.  Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.

Authors:  Alexandre J Debacker; Jon Voutila; Matthew Catley; David Blakey; Nagy Habib
Journal:  Mol Ther       Date:  2020-06-17       Impact factor: 11.454

Review 3.  Endocytic mechanisms for targeted drug delivery.

Authors:  Lisa M Bareford; Peter W Swaan
Journal:  Adv Drug Deliv Rev       Date:  2007-06-28       Impact factor: 15.470

Review 4.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

Review 5.  GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Authors:  Aaron D Springer; Steven F Dowdy
Journal:  Nucleic Acid Ther       Date:  2018-05-24       Impact factor: 5.486

Review 6.  Anti-miRNA oligonucleotides: A comprehensive guide for design.

Authors:  Joana Filipa Lima; Laura Cerqueira; Ceu Figueiredo; Carla Oliveira; Nuno Filipe Azevedo
Journal:  RNA Biol       Date:  2018-03-23       Impact factor: 4.652

Review 7.  Glycotargeting to improve cellular delivery efficiency of nucleic acids.

Authors:  Hongbin Yan; Kha Tram
Journal:  Glycoconj J       Date:  2007-02-01       Impact factor: 2.916

Review 8.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

9.  Distribution and anti-HBV effects of antisense oligodeoxynucleotides conjugated to galactosylated poly-L-lysine.

Authors:  Su-Jun Zheng; Sen Zhong; Jian-Jun Zhang; Feng Chen; Hong Ren; Cun-Liang Deng
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

10.  Transport and release of colloidal 3-mercaptopropionic acid-coated CdSe-CdS/ZnS core-multishell quantum dots in human umbilical vein endothelial cells.

Authors:  Jacopo M Fontana; Huijuan Yin; Yun Chen; Ricardo Florez; Hjalmar Brismar; Ying Fu
Journal:  Int J Nanomedicine       Date:  2017-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.